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Abstract
In the current report, we compared the specificities of antibody responses in sera from volunteers enrolled in three US NIH-
supported HIV vaccine trials using different immunization regimens. HIV-1 Env-specific binding antibody, neutralizing
antibody, antibody-dependent cell-mediated cytotoxicity (ADCC), and profiles of antibody specificity were analyzed for
human immune sera collected from vaccinees enrolled in the NIH HIV Vaccine Trial Network (HVTN) Study #041
(recombinant protein alone), HVTN Study #203 (poxviral vector prime-protein boost), and the DP6-001 study (DNA prime-
protein boost). Vaccinees from HVTN Study #041 had the highest neutralizing antibody activities against the sensitive virus
along with the highest binding antibody responses, particularly those directed toward the V3 loop. DP6-001 sera showed a
higher frequency of positive neutralizing antibody activities against more resistant viral isolate with a significantly higher
CD4 binding site (CD4bs) antibody response compared to both HVTN studies#041 and#203. No differences were found in
CD4-induced (CD4i) antibody responses, ADCC activity, or complement activation by Env-specific antibody among these
sera. Given recent renewed interest in realizing the importance of antibody responses for next generation HIV vaccine
development, different antibody profiles shown in the current report, based on the analysis of a wide range of antibody
parameters, provide critical biomarker information for the selection of HIV vaccines for more advanced human studies and,
in particular, those that can elicit antibodies targeting conformational-sensitive and functionally conserved epitopes.
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Introduction
Developing a safe and effective vaccine to control the global
transmission of Human Immunodeficiency Virus Type 1 (HIV-1)
remains one of the greatest challenges. The surprising outcome of
the STEP trial [1] demonstrated the danger of relying on one type
of vaccine and not paying equal attention to other vaccination
approaches [2–3]. Passive protection studies using neutralizing
monoclonal antibodies (mAbs) have demonstrated the utility of
antibodies in controlling infection in non-human primates
[4,5,6,7,8,9,10]. Furthermore, recently completed Phase III
human HIV-1 vaccine trial, RV144, using a canarypox vector
prime-recombinant envelope (Env) protein boost design, showed a
low but significant 31% reduction of infection compared with
placebo [11]. The mechanism for such protection in RV144 is
unknown but protective antibody is suspected to play a key role.
However, in-depth analysis of antibody responses elicited in
RV144 trial volunteers requires baseline information on the
qualities of human anti-Env antibody responses elicited by other
types of HIV-1 vaccines. Currently, such comparative analysis is
lacking in the literature. Recently, several new vaccination
approaches have significantly improved the magnitude or quality
of HIV-1 Env-specific antibody responses in humans and, thus,
provide the opportunity to compare the unique profiles of
antibody responses elicited by different HIV vaccine strategies.
In the current report, human vaccinee sera from three HIV-1
vaccine studies using different immunization approaches (Table 1)
were analyzed for the relative levels of binding and neutralizing
antibodies, the fine specificities of antibodies present in each
serum, and the ability to mediate other potentially protective
processes, including complement activation and Antibody-Depen-
dent Cell-mediated Cytoxicity (ADCC). Our results indicated that
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each HIV vaccine regimen can elicit unique profile of antibody
responses. This finding will be very useful to improve the design of
HIV vaccines to elicit the optimal protective antibody responses in
humans.
Results
All three candidate HIV vaccines included in the current
analysis were designed to elicit HIV-1 Env-specific antibody
responses (Table 1). HVTN 203 was an early phase clinical study
using a canarypox prime-protein boost regimen prior to the full-
scale RV144 efficacy trial. Volunteers from HVTN203 (Group B)
received the canarypox vector expressing a clade B Env, and were
boosted with a bivalent clade B/B Env protein formulation from
HIV-1 isolates, MN, and GNE8 [12], whereas RV144 expressed a
clade E Env by canarypox vector, which was then boosted with
bivalent clade B/E Env proteins [11]. Volunteers in the HVTN
203 trial received a total of four canarypox vector immunizations
in addition to two protein boosts adjuvanted with alum that were
overlapped with the last two canarypox immunizations. Protein
boosts consisted of the same recombinant Env protein vaccine that
failed to show protective efficacy in a Phase III clinical trial when
used alone [13]. HVTN 041 tested the immunogenicity of
recombinant Env protein derived from the HIV-1 isolate W61D,
adjuvanted in AS02A, without any prime immunizations [14]. The
DP6-001 trial used a DNA prime-recombinant protein boost
immunization approach delivering a 5-valent Env formulation
from HIV-1 isolates of clades A, B, C, and E [15]. Human
volunteers were first immunized three times with Env-expressing
DNA vaccines, followed by two boosts using matched recombinant
Env proteins (gp120) in QS-21 adjuvant.
Neutralizing antibody activity has been a key parameter in HIV
vaccine research to measure the protective potential of immune
sera specific for HIV-1 Env antigens [16,17]. Results of
neutralizing antibody activities in three sets of sera included in
the current report were previously reported and showed diverse
profiles [12,14,15]. In contrast to sera from the DP6-001 study,
which were capable of neutralizing a broad range of T-cell line
adapted (TCLA) and primary HIV-1 isolates [15], sera from the
HVTN 041 and HVTN 203 studies was only capable of
neutralizing autologous and TCLA viral strains [12,14]. Because
previous neutralizing activity analyses from each trial were done in
different assay systems, making direct comparisons difficult, a new
but limited set of neutralization assays were conducted by using
pseudotyped viruses expressing three model HIV-1 primary Env
antigens with varying degrees of sensitivity to neutralization to
confirm the previously reported neutralizing patterns for these
three sets of human sera. No extensive NAb analysis was done in
the current study, as they have been done in previously published
reports [12,14,15].
The vast majority of all sera tested, including 11 out of 12 (92%)
from the HVTN 041 study, 10 out of 12 sera (83%) from the
HVTN 203 study, and 20 out of 21 (95%) from the DP6-001
study, were capable of neutralizing SF162, a primary isolate highly
sensitive to neutralization (Fig 1A). Geometric mean ID50 titers
were 1:164 for HVTN 041, 1:62 for the HVTN 203 trial sera, and
1:104 for DP6-001. Sera from the HVTN 041 trial were
significantly more potent than those from the HVTN 203 study
against the sensitive isolate SF162 (p = 0.027), but not significantly
different from DP6-001.
Neutralizing activities against SS1196, a primary isolate that is
moderately sensitive to neutralization, allowed for some differen-
tiation of the neutralization potential of each trial sera (Fig 1B).
Only 4 of the 12 sera (33%) from the HVTN 203 trial were
capable of neutralizing SS1196 at a 1:10 dilution but 8 of the 12
sera (67%) from the HVTN 041 trial were capable of neutralizing
this virus. In contrast, 18 of the 21 sera (86%) from the DP6-001
trial were capable of neutralizing SS1196. Both the HVTN 041
Table 1. Summary of vaccine regimens.
Trial Prime Immunizations Boost Immunizations HIV-1 strains Adjuvant
Type Dose Weeks Type Dose (mg) Weeks
HVTN 041 N/A N/A N/A gp120 protein 5, 20, or 100 0, 4, 12 W61D AS02A
#
HVTN 203 Canarypox 107.26 TCID50 0, 4, 12, 24 gp120 protein 600 12, 24 MN, GNE8 Alum
DP6-001 DNA 1.2 mg 0, 4, 12 gp120 protein 375 20, 28 A, B, Bal, C, E* QS21
# QS-21 & 3D-MPL in o/w emulsion.
*A: 92UG037 B: 92US715 Bal: Ba-L C:96ZM651 E: 93TH976.
doi:10.1371/journal.pone.0013916.t001
Figure 1. Confirmation of neutralizing activities against
representative HIV isolates. Neutralization antibody titers at 50%
inhibition for each serum are shown against either SF162 (A) or
SS1196.1 (B). Neutralizing activities against SC422661.8 (C) is shown as
the fractions of individual sera from each trial either capable of
achieving at least 50% inhibition of infection at a 1:10 serum dilution
(shaded portion) or unable to achieve 50% inhibition (open portion). All
p values reaching significance (p,0.05) are presented in the figure. All
other comparisons did not reach significant based upon Kruskal-Wallis
and Dunn’significance tests.
doi:10.1371/journal.pone.0013916.g001
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and DP6-001 trials elicited higher titers than the HVTN 203 trial
(p = 0.02 and p= 0.03, respectively).
The third pseudotyped virus tested in the current analysis
expressed Env from the HIV-1 isolate, SC422661.8, a Tier 2 virus
representative of those found shortly after the establishment of
HIV-1 infection and known to be highly resistant to neutralization
[18]. A significant drop of neutralizing activities was observed with
sera from all three vaccine trials against this virus (Fig 1C). None of
the sera from the HVTN 203 trial were capable of reaching 50%
neutralization at the lowest dilution tested (1:10). Similarly,
neutralizing activity against this isolate was only observed in two
sera (17%) from the HVTN 041 trial. However, 10 of the 21 sera
(48%) from the DP6-001 trial were capable of neutralizing
SC422661.8 at a 1:10 dilution. This occurred despite the fact that,
on average, individuals in the DP6-001 had either lower or
equivalent titers of Env-specific binding antibodies when com-
pared to other two trial sera (Fig 2 below). The lack of neutralizing
activity from the HVTN 203 and 041 trials against more resistant
isolates, and the low titer neutralization seen in the samples from
the DP6-001 trial are both consistent with previously reported
neutralization profiles [12,14,15].
In order to understand what features of the antibody responses
elicited by each of these sera may be responsible for the difference
in their neutralization profiles, a wide spectrum of analyses were
conducted to understand the quality of different sera. The first was
Env-specific binding antibodies. The gp120 protein from the clade
B JR-FL strain was chosen as the model antigen to examine
binding titers because it is derived from a well-characterized
primary isolate and while each trial tested here was formulated
with at least one clade B component, JR-FL was not a component
in any of the formulations. Antibody levels generated by the
HVTN 041 formulation were found to be significantly higher than
the titers of binding antibodies generated in either the HVTN 203
or DP6-001 clinical trials (p = 0.035 and p= 0.0003, respectively)
(Fig 2), suggesting that gp120 adjuvanted with AS02A is an
exceptionally immunogenic formulation.
Antibodies directed to CD4 inducible (CD4i) epitopes are
frequently elicited in HIV-infected individuals [19] although their
role in controlling viral infection is currently unknown. Prior
exposure of pseudovirus to soluble CD4 (sCD4) can expose CD4i
epitopes, such as the co-receptor binding site, on the viral envelope
[20]. Sera from each trial included in the current study were
assayed for their ability to outcompete binding to 17b, a mAb that
targets the co-receptor binding site. High frequency and titers of
17b-like antibodies were detected in all three vaccine trials (Fig 3A).
Seven out of 12 sera (58%) from the HVTN 203 trial, 9 out of 12
(75%) from HVTN 041, and 17 out of 21 (81%) from DP6-001
were able to outcompete binding to 17b. Interestingly, those sera
that did compete did so at high titer, indicating an abundance of
antibodies with this specificity.
Next assay evaluated if the CD4i antibodies found in the sera
are functional in a modified neutralization assay. Pseudotyped
viruses expressing Env from the JR-FL isolate were treated with
sCD4 prior to incubation with serum. While without prior sCD4
treatment, JR-FL was difficult to neutralize by sera from all three
trials (Fig. 3B), significant neutralizing activities against JR-FL
Env pseudotyped viruses upon exposure to sCD4 were found in
these sera: 7 out of 12 (58%) from HVTN 203, 10 out of 12 (83%)
from HVTN 041, and 20 out of 21 (95%) from DP6-001 with
positive neutralizing activities (Fig 3C). Geometric mean
neutralizing titers for HVTN 203, HVTN 041, and DP6-001
were 1:28, 1:44, and 1:49, respectively. This data suggests that
under the proper conditions, CD4i antibodies present in vaccinee
sera would be capable of neutralizing heterologous isolates of
HIV-1.
Because it has been reported that sCD4 treatment leads to
increased exposure of the V3 loop [21], we attempted to
determine if the neutralizing activity observed after sCD4
treatment was due to recognition of the V3 loop or recognition
of the co-receptor binding site by the 17b-like antibodies detected
through competition. Vaccinee immune sera were incubated with
a synthetic peptide matched to the V3 loop sequence of the JR-FL
Env prior to the exposure of sCD4-treated JR-FL. This resulted in
a slight drop in the geometric mean NAb titer of HVTN 203 sera
to 26, of HVTN 041 sera to 25, and of DP6-001 sera to 34
(Fig 3D). This drop in potency was also accompanied by a drop in
the frequency of positive neutralizing sera to 6 out of 12 sera (50%)
in the HVTN 041 trial and to 16 out of 21 (76%) in the DP6-001
trial (Fig 3D). This data indicates that both V3 and co-receptor
binding site antibodies play a role in neutralizing the sCD4-treated
JR-FL virus.
Competitive binding assays were conducted against known
broadly neutralizing mAbs. Minimal competition was seen
against the glycan-specific 2G12 mAb (Fig 4A). None of the 12
sera from the HVTN 041 trial, 2 of the 12 sera (17%) from
HVTN 203, and 5 of 21 (24%) from DP6-001 outcompeted
binding to 2G12. In contrast, antibodies with specificities similar
to that of the V3-specific mAb, 447-52D, were elicited nearly
ubiquitously in all of the vaccinee sera tested (Fig 4B). The
geometric mean competitive binding titers against 447-52D were
1:108 for the HVTN 203 sera, 1:409 for HVTN 041, and 1:187
for DP6-001. Statistically significant differences in the titers of
V3-directed antibodies were observed in the HVTN 041 sera
relative to the HVTN 203 sera (p = 0.008) and DP6-001 sera
(p = 0.046).
A unique profile of CD4bs-directed antibodies was observed
upon examination of the ability of the immune sera to outcompete
binding against mAb b12 (Fig 4C). Only 4 out of 12 sera (33%)
from either the HVTN 203 trial or HVTN 041 generated an
antibody response capable of outcompeting binding to b12.
However, 20 out of 21 sera (95%) from the DP6-001 trial were
capable of outcompeting binding to b12 and did so with
Figure 2. Geometric mean endpoint binding titers of sera from
each of three human vaccine trials against a clade B
recombinant gp120 protein (JR-FL). Error bars indicate standard
error.
doi:10.1371/journal.pone.0013916.g002
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significantly higher titers, sometimes exceeding a 1:500 dilution
(p,0.001 against both HVTN 041 and HVTN 203 sera).
Additional functions of gp120-specific antibodies were analyzed.
Immune sera elicited by all three vaccine regimens were capable of
mediating ADCC function in an equivalent fashion with 19–21%
lysis of the recombinant gp120 protein pulsed CEMNKr target
cells (Fig. 5). An additional intrinsic characteristic of antigen-
specific antibody is the ability to mediate activation of the
complement pathway. Complement activation by gp120-specific
antibody was conducted for sera from all three trials; however,
they all activated complement in a similar fashion. A represen-
tative assay result is shown in Fig. 6A–B. A summary of the
antibody profiles for each set of immune sera analyzed in the
current study is provided (Table 2).
Discussion
In the current report, a side-by-side comparison was conducted
on the quality of human antibody responses elicited by three
candidate AIDS vaccines focusing on HIV-1 Env-specific
antibodies. Vaccines from all three studies had a gp120 protein
vaccine component but only two of the studies included priming
immunizations using either a viral vector- or DNA-based vaccine.
Although the sample sizes are relatively small, our results suggest
Figure 3. Analysis of antibodies against CD4 inducible (CD4i) epitopes. A) The presence of co-receptor binding site-directed antibodies was
assayed by competition with the mAb, 17b. Competition titer indicates the serum dilution capable of outcompeting 50% of pseudoviral binding to
17b. B) Neutralizing antibody titers against HIV-1 JR-FL isolate without sCD4 treatment. C) Neutralizing antibody titers against HIV-1 JR-FL isolate with
sCD4 treatment. D) Effect of V3 peptide treatment on neutralizing activity against sCD4-treated JR-FL.
doi:10.1371/journal.pone.0013916.g003
Figure 4. Specificity of vaccine-induced antibody responses as determined through mAb competition. The ability of serially diluted
human immune serum to outcompete binding of mAb to a JR-FL & VSV-G pseudotyped virus was measured. Competition titers indicate the serum
dilution preventing 50% of pseudoviral binding to the mAb. A) Competition with carbohydrate-specific mAb, 2G12. B) Competition with V3 loop-
specific mAb, 447-52D. C) Competition with CD4bs-specific mAb, b12.
doi:10.1371/journal.pone.0013916.g004
Ab Specificity HIV Vaccines
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that antibody profiles elicited by each vaccination regimen are
different. This information is valuable for the development of
AIDS vaccines with potential to elicit protective antibody
responses.
It has been shown in many published studies that passive
transfusion of antibodies in non-human primate models can
provide protection against challenge [4,5,6,7,8,9,10], but the real
challenge is that there is limited information on the antibody
specificities which may have contributed to such protection. This
knowledge is important because it may contribute to the design of
more effective vaccine antigens.
All three vaccines generated a high titer binding antibody
response. HVTN trial 041 volunteers had the highest Env-specific
serum IgG titers. Previous studies using recombinant gp120
proteins alone adjuvanted in alum did not generate high binding
antibodies [13]. Therefore, it is very likely that the strong adjuvant
effect of AS02A (MPL and QS21 formulated in o/w emulsion)
played an important role in the high immunogenicity observed for
this gp120 protein-based vaccine.
The levels of binding antibody did not correlate with the
presence or titer of neutralizing antibodies against a panel of
heterologous isolates. Consistent with previous reports [12,14,15],
the sera from HVTN 041 and HVTN 203 trials were, for the most
part, only capable of neutralizing sensitive isolates of HIV-1,
whereas sera from the DP6-001 displayed neutralization activities
against more resistant isolates.
In an attempt to explain this disparity, the fine specificity of
antibodies elicited by each trial was characterized. While
antibodies specific for glycan, CD4i, and V3 loop epitopes on
gp120 were all found at relatively similar levels among three sets of
immune sera, antibodies specific for the CD4bs were found more
frequently and in significantly higher titer in the DP6-001 study.
This may be important as CD4bs antibodies were found
responsible for the broad neutralizing activities in HIV-infected
patients [22].
Very few differences were observed when other biological
functions, such as complement activation and ADCC activity, were
determined. This somewhat contradicts previous data indicating
that the canarypox prime–recombinant Env protein boost was more
effective in eliciting higher levels of binding antibody and higher
frequencies of ADCC responses than the same recombinant Env
when used alone [23,24]. However, the immunogenicity of
recombinant Env proteins used in those studies was clearly less
optimal as shown by low levels of binding antibodies to the V3 loop.
The reason for this difference is not entirely clear but a more
immunogenic recombinant Env formulation with a potent adjuvant
system may be responsible for the high binding titers and high
frequency of ADCC observed in HVTN 041 sera. However, this
finding does not change the fact that canarypox prime–recombinant
Env boost is also highly immunogenic although it is not more
effective in generating ADCC than recombinant protein vaccines
when optimally formulated.
Sera from HVTN 203 had the least unique antibody profile. It
is less effective than DP6-001 sera in eliciting conformationally-
sensitive antibodies and neutralizing activity, and less effective at
raising binding antibody responses than HVTN 041 sera. It is not
clear whether these differences between the canarypox vector
prime and the DNA vaccine prime can be attributed to the fact
that the canarypox vector expresses multiple unrelated viral vector
proteins in addition to the HIV-1 Env while priming with the
DNA vaccine only focuses on the expression of Env.
Since the same canarypox prime-recombinant Env protein
boost approach was used in the recent RV144 trial which showed
statistically significant protection against HIV-1 in an efficacy field
Figure 5. Ability of vaccinee sera to mediate ADCC activity.
CEMNKr target cells were pulsed with gp120 prior to exposure of
vaccine serum at a 1:100 dilution. Target cell lysis indicates the ability of
vaccinee serum to mediate cell killing by PBMC from a normal human
donor. Dotted line indicates background cell lysis observed with a
normal human sera control.
doi:10.1371/journal.pone.0013916.g005
Figure 6. The ability of Env-specific antibodies to activate the complement cascade present in complement intact normal human
sera was determined using deposition of C4 as a marker for complement activation. A representative plot with data from a single
individual from each trial is shown. A) gp120-specific IgG measurement and B) C4 detection in the same testing sera.
doi:10.1371/journal.pone.0013916.g006
Ab Specificity HIV Vaccines
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trial, the results presented in the current report raise several
interesting questions. If a canarypox prime-recombinant Env
protein boost approach indeed offers any unique protective benefit
over the other two approaches, it is then necessary to identify new
biomarkers other than those included in the current study since
none stood out as a unique marker for the success of the HVTN
203 trial vaccine. Alternatively, either of the two other HIV
vaccines evaluated in the current study may have the potential to
provide even better protection than the canarypox prime-
recombinant Env protein boost approach if the higher responses
in certain assays observed only in the HVTN 041 or DP6-001 trial
sera are any indication. Additional late phase clinical studies are
needed to answer these questions. However, since the current
report showed that each vaccination approach has a relatively
specific antibody response profile, it may become feasible to start
linking the efficacy of any future vaccine formulation to the
antibody profile it exhibits.
The current report also pointed to a great need to expand the
scope of research to include diverse types of antibody responses
when a candidate HIV vaccine is evaluated. The presence of
neutralizing antibodies has been used almost exclusively to judge
the protective potential of vaccine-induced antibody responses.
Other parameters, especially the induction of conformation-
dependent antibodies, can provide unique insight to differentiate
the quality of antibodies elicited by vaccines.
In recent studies of HIV-infected individuals with broadly
neutralizing activity, the neutralizing fraction of sera has often
been mapped to those antibodies directed towards the CD4bs
[22,25,26,27]. Several new broadly neutralizing mAbs were
developed targeting the CD4bs [28]. Two other new mAbs,
PG9 and PG16, also target at conformationally sensitive epitopes
which were formed by domains from different adjacent gp120
antigens [29]. Other non-HIV recombinant protein-based vac-
cines, such as HBV and HPV vaccines, also require highly
conformational antigens [30,31,32]. Because of this, it is exciting
to observe the elicitation of antibodies against conformationally
sensitive CD4bs as those seen in HIV-infected individuals through
the use of a DNA prime-protein boost regimen. The unique
antibody profile and ability to better neutralize primary isolates
provides evidence that the DNA prime-protein boost regimen
offers another promising heterologous prime-boost platform for
further HIV vaccine development in addition to the recent RV144
canarypox prime-protein boost regimen.
Materials and Methods
HIV vaccine trial vaccinee sera
Human serum samples from the HVTN 041 (NCT00027365)
and 203 (NCT00007332) trials [12,14] were obtained through an
ancillary study agreement with the US NIH HIV Vaccine Trials
Network (HVTN). Sera from DP6-001 study (NCT00061243)
were collected as previously described [15]. All serum samples
used in this study were collected two weeks after the final
immunization.
Ethics Statement
Human serum samples used in the current study were provided
by previously closed human clinical trials. The samples used for
the current analysis do not have any identifying information about
the volunteers that were included in the original studies. Two of
these previously closed studies, HTVN trials (HVTN 203
(NCT00007332) and HVTN 041 (NCT00027365)), were con-
ducted by US National Institute of Health’ HIV Vaccine Trial
Network (HVTN). The Institutional Review Board (IRB) of each
participating site of these trials reviewed and approved these study
protocols and informed consent forms according to ethics
requirements established by HVTN. For the DP6-001 study
(NCT00061243), study protocol and informed consent were
reviewed and approved by IRB at the University of Massachusetts
Medical School (UMMS), Worcester, MA, USA. For each study,
IRB approved written consent was obtained from all study
participants. UMMS IRB has reviewed current study of serum
analysis and waived requirement of informed consent since these
sera were unused samples from previously closed studies without
any volunteer identifier information.
Antibodies
Monoclonal antibodies used in the current study were provided
by Drs. Dennis Burton (b12), Susan Zolla-Pazner (447-52D), and
James Robinson (17b), and NIH AIDS Research & Reference
Reagent Program (2G12).
Cells and Cell Lines
TZM-bl and CEMNKr cells were obtained from the NIH AIDS
Research and Reference Reagent program. PBMC used as
effector cells in the ADCC assays were obtained from Dr.
Marjorie Robert-Guroff.
Table 2. Profiles of antibody responses elicited by three HIV vaccine regimens.
HVTN 041 (Protein alone) HVTN 203 (Viral vector + protein) DP6-001 (DNA + protein)
NAb against sensitive primary virus High titer NAb Low titer NAb High titer NAb
NAb against less resistant primary virus Positive NAb with moderate frequency Occasionally positive NAb Positive NAb with moderate frequency
NAb against more resistant primary virus Occasionally positive NAb No detectable NAb Positive NAb with moderate frequency
Serum gp120-specific binding IgG Significantly high level binding antibodies High level binding antibodies Moderately high level binding antibodies
Ab against CD4i Positive Positive Positive
Ab competing mAb 2G12 Undetectable Rare Occasional
Ab competing mAb 447-52D Significantly high level Ab Moderately high level Ab High level Ab
Ab competing mAb b12 Occasional Occasional Frequent
ADCC activity Positive Positive Positive
Complement activation Easily detected Easily detected Easily detected
doi:10.1371/journal.pone.0013916.t002
Ab Specificity HIV Vaccines
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Enzyme-linked Immunosorbent Assay
Endpoint binding titers were determined by applying serially
diluting serum samples from each trial to JR-FL gp120-coated
microtiter plates at 1 mg/mL. Bound gp120-specific IgG was
detected using a biotinylated anti-human antibody and a
subsequent incubation with a streptavidin-HRP. After develop-
ment with a 3,395,59-tetramethylbenzidine substrate solution,
endpoint titers were defined as the last dilution of sera providing
at least twice the background optical density of a normal human
sera control.
Neutralization Assays
Neutralization assays were done as previously described [33].
Briefly, 200 TCID50 was incubated with human sera for 1 hr,
followed by the addition of 105 TZM-bl cells in a final
concentration of 20 mg/mL DEAE Dextran. Plates were incubat-
ed at 37uC for 48 hours and developed with luciferase reagent
(Promega). Neutralization was calculated as the percent change in
luciferase activity in the presence of normal human sera versus
that of luciferase activity in the presence of immune sera [(NHS
RLUs – Immune RLUs)/(NHS RLUs)]*100. In some neutraliza-
tion assays, JR-FL pseudovirus was treated with 5 mg/mL sCD4
for 1 hr at 37uC prior to the addition of serum. When peptide
adsorptions were reported, serum was incubated with a consensus
clade B V3 peptide (CTRPNNNTRKSIHIGPGRAFYTTGEIIG-
DIRQAHC) at 25 mg/mL for 1 hr at 37uC prior to the addition of
virus.
Competitive Binding Assays
Competitive binding assays were performed as previously
described [34,35] with minor modifications. Pseudovirions bearing
the JR-FL Env and Vesicular Stomatitis Virus were incubated
with serial dilutions of human vaccinee sera prior to the addition
to a mAb-coated microtiter plate. Virus/sera mixture was then
incubated in the ELISA wells for 3 hrs at room temperature.
Plates were washed and 10,000 TZM-bl cells per well were
overlayed and incubated for 48 hrs at 37uC. Competition activity
is reported as the serum dilution at which the luciferase signal is
reduced by 50%.
ADCC
The ability of serum from immunized individuals to mediate
ADCC activity was performed as previously described with minor
modifications [36]: 16106 CEMNKr cells were dual stained with
2.561026 M PKH-26 (Sigma) and 561028 M CFSE (Molecular
Probes, Invitrogen). The labeled cells were pulsed with 5 mg
gp120, and exposed to vaccine sera prior to incubation with
PBMC from an HIV negative donor for 4 hours. Cells were then
subjected to flow cytometric analysis where CEMNKr target cell
lysis was defined as the percentage of CEMNKr cells in the PKH-
26hi population that lost CFSE fluorescence.
Detection of complement activation
The downstream product of complement activation, C4, was
detected in an ELISA-based assay. ELISAs were performed as
described above, where JR-FL gp120 protein was coated on a
microtiter plate and exposed to serial dilutions of heat inactivated
vaccinee sera. After washing, intact normal human serum was
used as a source of complement and was incubated on the plate at
a 1:100 dilution for 1 hr at RT. Deposited C4 was then detected
with a goat anti-C4 antibody (1:1000 dilution for 1 hr incubation
at RT). An AP conjugated anti-goat secondary antibody was used
for final detection.
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